A European consensus statement says antithrombotic treatment for acute coronary syndromes should adjust for sex differences ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top stocks sold by hedge funds. On July 28, Bristol Myers, in ...

NSCLC represents 80% of lung cancer cases and is the leading cause of cancer-related mortality globally. This designation is ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.18%, which means the company has less short interest than most of its peers. Did ...

Among 41 patients with this rare and highly aggressive RCC subtype, the objective response rate (ORR) was 56% with the ...

The FDA has granted Breakthrough Therapy Designation to Bristol Myers Squibb (BMY) and SystImmune’s experimental drug iza-bren for treating advanced EGFR-mutant lung cancer after prior therapies fail, ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

With Trump's backing, the pharma industry is leaning into the idea of more "direct-to-consumer" sales. But experts say the ...

Systlmmune and BMS’ ACD treats patients with previously treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer.